Galaxy Biomedical Investment Co.,Ltd. Posted 47.7 Million Yuan Net Loss in First Three Quarters of 2022

Galaxy Biomedical Investment Co.,Ltd. (北海银河生物产业投资股份有限公司) (000806.SZ) reported a net loss of 47.7 million yuan in the first three quarters of 2022, narrowing 70.2% year-on-year.

Meanwhile, the company posted 1.1 billion yuan in revenue, up 43.8% year-on-year.

At the end of the reporting period, it had 1.8 billion yuan in total assets and 2.8 billion yuan in total liabilities, with a liability-to-asset ratio of 152.3%.